<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>BMS reunites R&amp;D divisions under Cristian Massacesi, while Robert Plenge departs — Live Feed</title><link>https://www.live-feeds.com/feed/bms-reunites-r-d-divisions-under-cristian-massacesi-while-robert-plenge-departs</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/bms-reunites-r-d-divisions-under-cristian-massacesi-while-robert-plenge-departs/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>Bristol Myers Squibb Reunites R&amp;D Divisions and Names Cristian Massacesi</title><link>https://www.live-feeds.com/feed/bms-reunites-r-d-divisions-under-cristian-massacesi-while-robert-plenge-departs</link><guid isPermaLink="false">https://www.live-feeds.com/feed/bms-reunites-r-d-divisions-under-cristian-massacesi-while-robert-plenge-departs#u203959</guid><pubDate>Mon, 16 Nov 2026 12:21:44 +0000</pubDate><description>Bristol Myers Squibb is reuniting its research and development divisions under Cristian Massacesi, leading to the departure of research chief Robert Plenge. The pharmaceutical company plans to implement this unified organizational structure on Jan. 1, 2027. This leadership shakeup merges the company scientific and clinical teams into a single operational framework. The consolidation represents an evolution of the corporate structure as leadership prepares for upcoming patent expirations.Why it mattersThe reorganization shifts how the company manages drug discovery and clinical trials by combin</description></item>
</channel></rss>